{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:26:40Z","timestamp":1770823600723,"version":"3.50.1"},"reference-count":41,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Low-molecular-weight and unfractionated heparins are frequently used to treat venous thromboembolism, but it is not known whether they are equally effective in inhibiting in vivo generation of thrombin. In this multicenter trial, 1048 patients were randomized to intravenous unfractionated heparin (group A), twice daily low-molecular-weight heparin (reviparin) for 1 week (group B), or once daily reviparin for 4 weeks (group C). All patients received vitamin K antagonists. Blood samples withdrawn at the baseline and at weeks 1 and 3 were analyzed using markers of in vivo thrombin generation and other coagulation parameters. During the first 3 weeks symptomatic recurrent deep vein thrombosis\u2013pulmonary embolism (DVT\/PE) occurred in 17 (4.5%) of 375 patients in group A compared with 4 (1.0%) of 388 patients in group B, and 9 (2.4%) of 374 patients in group C. Forty percent of patients in group A, 53.4% in group B, and 53.5% in group C showed 30% or greater reduction in thrombus size assessed by venography. Patients in group B had significantly greater reduction in D-dimer, prothrombin fragments 1 and 2 (F1\u2009+\u20092), endogenous thrombin potential (ETP), and thrombin-antithrombin (TAT) complexes compared to groups A and C. Greater release of tissue factor pathway inhibitor (TFPI) and reduction in levels of thrombin activatable fibrinolysis inhibitor (TAFI) and fibrinogen were significantly more pronounced in group C patients. Reviparin administered twice daily plus vitamin K antagonist is more effective in inhibiting in vivo thrombin generation compared to intravenous unfractionated heparin plus vitamin K antagonist, and reviparin once daily produced significantly higher TFPI release and greater reduction in TAFI and fibrinogen levels.<\/jats:p>","DOI":"10.1182\/blood.v99.6.1965","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T21:48:18Z","timestamp":1033508898000},"page":"1965-1970","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis"],"prefix":"10.1182","volume":"99","author":[{"given":"Vijay V.","family":"Kakkar","sequence":"first","affiliation":[{"name":"From the Thrombosis Research Institute, Chelsea, London, United Kingdom; Haemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois; Knoll AG, Ludwigshafen, Germany; and International Institute of Thrombosis and Vascular Diseases, Frankfurt, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra A.","family":"Hoppenstead","sequence":"additional","affiliation":[{"name":"From the Thrombosis Research Institute, Chelsea, London, United Kingdom; Haemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois; Knoll AG, Ludwigshafen, Germany; and International Institute of Thrombosis and Vascular Diseases, Frankfurt, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawed","family":"Fareed","sequence":"additional","affiliation":[{"name":"From the Thrombosis Research Institute, Chelsea, London, United Kingdom; Haemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois; Knoll AG, Ludwigshafen, Germany; and International Institute of Thrombosis and Vascular Diseases, Frankfurt, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zbigniew","family":"Kadziola","sequence":"additional","affiliation":[{"name":"From the Thrombosis Research Institute, Chelsea, London, United Kingdom; Haemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois; Knoll AG, Ludwigshafen, Germany; and International Institute of Thrombosis and Vascular Diseases, Frankfurt, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Scully","sequence":"additional","affiliation":[{"name":"From the Thrombosis Research Institute, Chelsea, London, United Kingdom; Haemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois; Knoll AG, Ludwigshafen, Germany; and International Institute of Thrombosis and Vascular Diseases, Frankfurt, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roumen","family":"Nakov","sequence":"additional","affiliation":[{"name":"From the Thrombosis Research Institute, Chelsea, London, United Kingdom; Haemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois; Knoll AG, Ludwigshafen, Germany; and International Institute of Thrombosis and Vascular Diseases, Frankfurt, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans K.","family":"Breddin","sequence":"additional","affiliation":[{"name":"From the Thrombosis Research Institute, Chelsea, London, United Kingdom; Haemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois; Knoll AG, Ludwigshafen, Germany; and International Institute of Thrombosis and Vascular Diseases, Frankfurt, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021221322577500_B1","first-page":"30","article-title":"Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.","volume":"16(suppl 2)","author":"Holm","year":"1986","journal-title":"Haemostasis."},{"key":"2020021221322577500_B2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00280041","article-title":"Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.","volume":"39","author":"Handeland","year":"1990","journal-title":"Eur J Clin Pharmacol."},{"key":"2020021221322577500_B3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1055\/s-0038-1647348","article-title":"Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).","volume":"64","author":"Bratt","year":"1990","journal-title":"Thromb Haemost."},{"key":"2020021221322577500_B4","first-page":"220","article-title":"Treatment of deep vein thrombosis by fixed doses of a low molecular weight heparin (CY216).","volume":"20(suppl 1)","author":"Prandoni","year":"1990","journal-title":"Haemostasis."},{"key":"2020021221322577500_B5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0038-1647660","article-title":"A randomised trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis: a collaborative European multicentre study.","volume":"65","year":"1991","journal-title":"Thromb Haemost."},{"key":"2020021221322577500_B6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJM199204093261502","article-title":"Subcutaneous low-molecular-weight-heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.","volume":"326","author":"Hull","year":"1992","journal-title":"N Engl J Med."},{"key":"2020021221322577500_B7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(92)91054-C","article-title":"Comparison of subcutaneous low-molecular-weight-heparin with intravenous standard heparin in proximal deep-vein thrombosis.","volume":"339","author":"Prandoni","year":"1992","journal-title":"Lancet."},{"key":"2020021221322577500_B8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archinte.1993.00410130045005","article-title":"Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.","volume":"153","author":"Simonneau","year":"1993","journal-title":"Arch Intern Med."},{"key":"2020021221322577500_B9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0038-1648836","article-title":"Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.","volume":"72","author":"Lindmarker","year":"1994","journal-title":"Thromb Haemost."},{"key":"2020021221322577500_B10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0038-1650553","article-title":"Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.","volume":"76","author":"Fiessinger","year":"1996","journal-title":"Thromb Haemost."},{"key":"2020021221322577500_B11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1365-2796.1996.18845000.x","article-title":"A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep venous thrombosis.","volume":"240","author":"Luomanmaki","year":"1996","journal-title":"J Intern Med."},{"key":"2020021221322577500_B12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM199603143341102","article-title":"Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home: the Tasman study.","volume":"334","author":"Koopman","year":"1996","journal-title":"N Engl J Med."},{"key":"2020021221322577500_B13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199603143341101","article-title":"A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.","volume":"334","author":"Levine","year":"1996","journal-title":"N Engl J Med."},{"key":"2020021221322577500_B14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJM199709043371001","article-title":"Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism.","volume":"337","author":"The Columbus Investigators","year":"1997","journal-title":"N Engl J Med."},{"key":"2020021221322577500_B15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM199709043371002","article-title":"A comparison of low molecular-weight heparin with unfractionated heparin for acute pulmonary embolism.","volume":"337","author":"Simonneau","year":"1997","journal-title":"N Engl J Med."},{"key":"2020021221322577500_B16","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJM200103013440902","article-title":"Effects of two low molecular weight heparin regimens on thrombus regression and recurrent venous thromboembolism in the treatment of acute deep vein thrombosis.","volume":"334","author":"Breddin","year":"2001","journal-title":"N Engl J Med."},{"key":"2020021221322577500_B17","first-page":"1018","article-title":"Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy.","volume":"89","author":"Marder","year":"1977","journal-title":"J Lab Clin Med."},{"key":"2020021221322577500_B18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/00001721-199312000-00006","article-title":"Effect of synthetic phospholipids on the response of the activated partial thromboplastin time to heparin.","volume":"4","author":"van den Besselaar","year":"1993","journal-title":"Blood Coagul Fibrinolysis."},{"key":"2020021221322577500_B19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/ajcp\/57.1.80","article-title":"Standardization for the therapeutic range for oral anticoagulants based on standard reference plasmas.","volume":"57","author":"Miale","year":"1972","journal-title":"Am J Clin Pathol."},{"key":"2020021221322577500_B20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0049-3848(75)90078-X","article-title":"Heparin cofactor activity measured with an amidolytic method.","volume":"6","author":"Odegard","year":"1975","journal-title":"Thromb Res."},{"key":"2020021221322577500_B21","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0049-3848(83)90108-1","article-title":"An immunoassay for human D-dimer using monoclonal antibodies.","volume":"31","author":"Rylatt","year":"1983","journal-title":"Thromb Res."},{"key":"2020021221322577500_B22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1055\/s-0038-1646768","article-title":"Determination of human anti-thrombin III complex in plasma with an enzyme linked immunosorbent assay.","volume":"59","author":"Dalzer","year":"1988","journal-title":"Thromb Haemost."},{"key":"2020021221322577500_B23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0038-1647475","article-title":"Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide.","volume":"65","author":"Pelzer","year":"1991","journal-title":"Thromb Haemost."},{"key":"2020021221322577500_B24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0049-3848(88)90340-4","article-title":"Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).","volume":"50","author":"Sandset","year":"1988","journal-title":"Thromb Res."},{"key":"2020021221322577500_B25","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1172\/JCI118315","article-title":"Carboxypeptidase as regulators of plasminogen system.","volume":"96","author":"Redlitz","year":"1995","journal-title":"J Clin Invest."},{"key":"2020021221322577500_B26","first-page":"629","article-title":"The routine determination of the endogenous thrombin potential, first results in different forms of hyper and hypocoagulability.","volume":"77","author":"Wielders","year":"1977","journal-title":"Thromb Haemost."},{"key":"2020021221322577500_B27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/01971529608005783","article-title":"An enzyme-linked immunosorbent assay (ELISA) for the measurement of activated factor VII (Hageman factor) in human plasma.","volume":"17","author":"Ford","year":"1996","journal-title":"J Immunoassay."},{"key":"2020021221322577500_B28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0005-2795(73)90098-6","article-title":"Subunit structure of the plasmin induced degradation products of cross linked fibrin.","volume":"295","author":"Gaffney","year":"1973","journal-title":"Biochim Biophys Acta."},{"key":"2020021221322577500_B29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.1989.tb22496.x","article-title":"Plasma anticoagulant mechanisms of heparin, heparin sulphate and duratan sulphate.","volume":"556","author":"Ofosu","year":"1989","journal-title":"Ann N Y Acad Sci."},{"key":"2020021221322577500_B30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0950-3536(05)80016-2","article-title":"Mechanisms of actions of low molecular weight heparins and heparinoids.","volume":"3","author":"Ofosu","year":"1993","journal-title":"Baillieres Clin Haematol."},{"key":"2020021221322577500_B31","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1016\/S0021-9258(19)43472-8","article-title":"The purification and mechanism of action of human antithrombin heparin co-factor.","volume":"248","author":"Rosenberg","year":"1973","journal-title":"J Biol Chem."},{"key":"2020021221322577500_B32","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1073\/pnas.76.7.3198","article-title":"Structure of the antithrombin-binding site of heparin.","volume":"76","author":"Lindahl","year":"1979","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021221322577500_B33","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.V94.7.2169.419k22_2169_2178","article-title":"\u201cNormal\u201d thrombin generation.","volume":"94","author":"Butenas","year":"1999","journal-title":"Blood."},{"key":"2020021221322577500_B34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(77)91429-5","article-title":"Heparin-induced decrease in circulating anti-thrombin III.","volume":"2","author":"Marciniak","year":"1977","journal-title":"Lancet."},{"key":"2020021221322577500_B35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(80)90538-3","article-title":"Anti-thrombin III and heparin.","volume":"1","author":"Kakkar","year":"1980","journal-title":"Lancet."},{"key":"2020021221322577500_B36","doi-asserted-by":"crossref","first-page":"14477","DOI":"10.1074\/jbc.270.24.14477","article-title":"Purification and characterisation of TAFI, a thrombin-activatable fibrinolysis inhibitor.","volume":"270","author":"Bajzar","year":"1995","journal-title":"J Biol Chem."},{"key":"2020021221322577500_B37","doi-asserted-by":"crossref","first-page":"27176","DOI":"10.1074\/jbc.273.42.27176","article-title":"A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor.","volume":"273","author":"Wang","year":"1998","journal-title":"J Biol Chem."},{"key":"2020021221322577500_B38","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1055\/s-0037-1615366","article-title":"Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact pathway of coagulation.","volume":"80","author":"Mosnier","year":"1998","journal-title":"Thromb Haemost."},{"key":"2020021221322577500_B39","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood.V95.9.2855.009k02_2855_2859","article-title":"Thrombin activatable fibrinolysis inhibitor and the risk of deep vein thrombosis.","volume":"95","author":"van Tilburg","year":"2000","journal-title":"Blood."},{"key":"2020021221322577500_B40","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4049\/jimmunol.165.2.1053","article-title":"Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas coboxypeptidase M is not.","volume":"165","author":"Sato","year":"2000","journal-title":"J Immunol."},{"key":"2020021221322577500_B41","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0037-1614029","article-title":"Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.","volume":"84","author":"Silveria","year":"2000","journal-title":"Thromb Haemost."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/6\/1965\/1681417\/1965.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/6\/1965\/1681417\/1965.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T12:32:56Z","timestamp":1622205176000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/6\/1965\/53533\/Randomized-trial-of-different-regimens-of-heparins"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,15]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,3,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.6.1965","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,3,15]]}}}